Corrigendum to "Effect of chiglitazar and sitagliptin on glucose variations, insulin resistance and inflammatory-related biomarkers in untreated patients with type 2 diabetes" [Diabetes Res. Clin. Pract. 183 (2022) 109171]. (August 2022)